Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) announced its earnings results on Tuesday. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.37 by $0.08, Zacks reports. The firm had revenue of $755.76 million for the quarter, compared to the consensus estimate of $746.62 million. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%.

Swedish Orphan Biovitrum Stock Performance

OTCMKTS:BIOVF opened at $43.15 on Thursday. The firm’s 50-day moving average is $40.10 and its 200-day moving average is $37.04. Swedish Orphan Biovitrum has a 52-week low of $27.06 and a 52-week high of $43.15. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.59 and a current ratio of 0.90. The company has a market cap of $15.36 billion, a price-to-earnings ratio of 331.95 and a beta of 0.35.

Analyst Ratings Changes

BIOVF has been the topic of several recent analyst reports. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, February 24th. BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a report on Tuesday, February 10th. Finally, Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Swedish Orphan Biovitrum currently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.